Thermo Fisher Scientific Inc. (TMO)
Thermo Fisher Scientific (TMO) Reports Next Week: Wall Street Expects Earnings Growth
Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thermo Fisher to Report Q3 Earnings: What's in the Cards?
TMO gears up for Q3 earnings, with revenue and EPS growth expected amid strong bioproduction demand, product innovations and clinical research strength.
All You Need to Know About Thermo Fisher (TMO) Rating Upgrade to Buy
Thermo Fisher (TMO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is This the Right Time to Add TMO Stock to Your Portfolio?
Thermo Fisher's growth gains momentum through innovation, acquisitions and broad end-market strength, but macroeconomic and currency risks remain.
Thermo Fisher Sees Stronger Demand, Calls 2026 an ‘Outstanding Year'
Thermo Fisher Scientific NYSE: TMO Chairman and Chief Executive Officer Marc Casper said the company is seeing improving demand across several end markets and expects 2026 to be an “outstanding year,” supported by stronger customer activity and operational execution.
Thermo Fisher Scientific Inc. (TMO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Thermo Fisher Scientific Inc. (TMO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Should You Continue to Hold TMO Stock in Your Portfolio?
Thermo Fisher's growth is gaining momentum as acquisitions strengthen its life sciences reach, but macro risks and competition remain concerns.
TMO Stock Could Gain Following the Launch of EMPAD G2 Detector
Thermo Fisher's EMPAD G2 detector enhances 4D STEM imaging speed, sensitivity and workflow integration, strengthening its Analytical Instruments portfolio.
Thermo Fisher Scientific: Biopharma Recovery And Share Gains Support The Upside
Thermo Fisher Scientific is rated a Buy, supported by accelerating organic growth and improving Pharma and Biotech end markets. TMO's recent acquisitions of Clario and Solventum's Filtration and Separation business expand capabilities, enabling greater share of customer spending and revenue synergies. Q2 2026 results showed 10% revenue growth, 5% organic growth, and improved margins, with Pharma and Biotech driving mid-single-digit gains.
Thermo Fisher Raises 2026 Outlook After Strong Second-Quarter Results
Thermo Fisher Scientific Inc. TMO raised its 2026 outlook after second-quarter earnings and revenues exceeded expectations. The update reflects stronger customer activity, better acquisition performance and improved operating leverage.
Unlocking Thermo Fisher (TMO) International Revenues: Trends, Surprises, and Prospects
Examine the evolution of Thermo Fisher's (TMO) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
How Thermo Fisher Is Riding Bioproduction and AI-Led Growth Trends
TMO is expanding bioproduction, AI tools and clinical data capabilities, but execution will be key as competition intensifies.
